NICE backs AstraZeneca’s Calquence for CLL
Recommendation offers new chemotherapy-free treatment options for these patients
Read More
Tag: chronic lymphocytic leukaemia
Calquence tops Imbruvica in chronic lymphocytic leukaemia study
BTK inhibitor demonstrated non-inferior progression-free survival compared to Imbruvica
Read More
EU OK for AZ’s Calquence in CLL
BTK inhibitor approved based on results from two phase III trials
Read More
EU expands scope of Imbruvica to include untreated CLL patients
Treatment naïve patients lived longer without disease progression with the Imbruvica-based regimen than those given a chemotherapy-based one
Read More
CAR-T therapies shine at ASH
Janssen’s JNJ-4528 and BMS’ liso-cel show 100% response rates
Read More
AZ’ Calquence trial to stop early after hitting endpoints
The drug was found to significantly increase the time patients live without disease progression.
Read More
FDA approves Imbruvica combination for chronic lymphocytic leukaemia
The FDA has approved AbbVie/Johnson & Johnson’s Imbruvica in combination with Roche’s Gazyva in treatment-naïve patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL).
Read More
Venetoclax gets NICE approval for chronic lymphocytic leukaemia
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Venclyxto to benefit thousands of adults with chronic lymphocytic leukaemia.
Read More
US clears Verastem’s Copiktra for blood cancers
Verastem Oncology’s Copiktra has been approved in the US for the treatment relapsed or refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma after at least two prior therapies.
Read More
US nod for Venclexta/Rituxan combo
US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen’s Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Read More
Janssen drops price of Imbruvica to secure NICE nod
It is looking likely that Janssen’s Imbruvica will be available to treat some people with chronic lymphocytic leukaemia (CLL) routinely on the NHS, after cost regulators issued draft guidelines endorsing its use.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
